In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Top Biotech Licensings of 2004

Executive Summary

Judging by the top ten biotech alliances of 2004, biotech's late-stage pipelines have largely been picked clean by Big Pharma licensees. The trend toward earlier stage deals among the top ten alliances in 2003 we noted last year has become even more prominent.

You may also be interested in...



Why Early-Stage Dealmaking is Hot

Big Pharma is in-licensing increasing numbers of preclinical and Phase I compounds despite the fact that their own early-stage productivity is up. Their goal is to increase shots on goal; to pay for the ballooning costs, however, they're increasingly willing to share downstream rights for near-term help on expenses.

Big Pharma Finds New Pipeline Source: Each Other

As Big Pharma's pipeline crunch continues, so does competition for late-stage licensing opportunities, driving up late-stage deal values. A notable trend behind these rising values is a spate of Big Pharma cross-licensing deals.

Top Biotech Licensings of 2003

We review the top ten biotech licensing deals by deal value signed in 2003.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV002515

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel